ALM patients with both MUC16 and TTN mutations had better prognosis (HR: 0.233; CI: 0.0779–0.697; p = 0.0092) than ALM patients with neither MUC16 nor TTN mutations. The gene discussed is MUC16; the disease is acral lentiginous melanoma.